Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer (Q34368408)

1 August 2017

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer (English)

1 reference

1 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

S M Larson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Michael J Morris

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Josef J Fox

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Daniel C Danila

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Susan F Slovin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jeffrey H Hager

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Peter J Rix

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Edna Chow Maneval

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Isan Chen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mithat Gönen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Martin Fleisher

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Charles L Sawyers

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Howard I Scher

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

3 September 2013

1 reference

Journal of Clinical Oncology

1 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

3525-3530

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

Increased survival with enzalutamide in prostate cancer after chemotherapy

12 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

ARN-509: a novel antiandrogen for prostate cancer treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Abiraterone and increased survival in metastatic prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

6 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Positron tomographic assessment of androgen receptors in prostatic carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Molecular determinants of resistance to antiandrogen therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782148

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24002508

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2013.50.1684

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24002508%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference